NASDAQ:RAPP Rapport Therapeutics (RAPP) Stock Price, News & Analysis $9.51 -0.53 (-5.28%) Closing price 04:00 PM EasternExtended Trading$9.52 +0.01 (+0.05%) As of 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Rapport Therapeutics Stock (NASDAQ:RAPP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rapport Therapeutics alerts:Sign Up Key Stats Today's Range$9.33▼$10.1550-Day Range$8.52▼$11.5552-Week Range$6.43▼$29.74Volume138,054 shsAverage Volume174,399 shsMarket Capitalization$347.10 millionP/E RatioN/ADividend YieldN/APrice Target$32.67Consensus RatingBuy Company OverviewRapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.Read More… Rapport Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreRAPP MarketRank™: Rapport Therapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 799th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingRapport Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRapport Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Rapport Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rapport Therapeutics are expected to grow in the coming year, from ($3.65) to ($3.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rapport Therapeutics is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rapport Therapeutics is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Rapport Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.20% of the float of Rapport Therapeutics has been sold short.Short Interest Ratio / Days to CoverRapport Therapeutics has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in Rapport Therapeutics has recently decreased by 1.98%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRapport Therapeutics does not currently pay a dividend.Dividend GrowthRapport Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.20% of the float of Rapport Therapeutics has been sold short.Short Interest Ratio / Days to CoverRapport Therapeutics has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in Rapport Therapeutics has recently decreased by 1.98%, indicating that investor sentiment is improving. News and Social Media1.9 / 5News Sentiment0.47 News SentimentRapport Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Rapport Therapeutics this week, compared to 2 articles on an average week. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Rapport Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $161,250.00 in company stock and sold $0.00 in company stock.Read more about Rapport Therapeutics' insider trading history. Receive RAPP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rapport Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RAPP Stock News HeadlinesRapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare ConferenceMay 27 at 7:00 AM | globenewswire.comRapport Therapeutics to Host 2025 Investor and Analyst DayMay 21, 2025 | globenewswire.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. May 28, 2025 | Porter & Company (Ad)Companies Like Rapport Therapeutics (NASDAQ:RAPP) Are In A Position To Invest In GrowthMay 17, 2025 | finance.yahoo.comRapport Therapeutics Reports Q1 2025 Financial ResultsMay 10, 2025 | tipranks.comOptimistic Buy Rating for Rapport Therapeutics Driven by Promising RAP-219 DevelopmentsMay 8, 2025 | tipranks.comPromising Clinical Developments and Strategic Initiatives Drive Buy Rating for Rapport Therapeutics, Inc.May 8, 2025 | tipranks.comRapport Therapeutics Reports First Quarter 2025 Financials and Provides Business UpdateMay 8, 2025 | globenewswire.comSee More Headlines RAPP Stock Analysis - Frequently Asked Questions How have RAPP shares performed this year? Rapport Therapeutics' stock was trading at $17.74 on January 1st, 2025. Since then, RAPP shares have decreased by 46.4% and is now trading at $9.51. View the best growth stocks for 2025 here. How were Rapport Therapeutics' earnings last quarter? Rapport Therapeutics (NASDAQ:RAPP) issued its earnings results on Thursday, May, 8th. The company reported ($0.68) earnings per share for the quarter, beating analysts' consensus estimates of ($0.77) by $0.09. When did Rapport Therapeutics IPO? Rapport Therapeutics (RAPP) raised $136 million in an initial public offering (IPO) on Friday, June 7th 2024. The company issued 8,000,000 shares at a price of $17.00 per share. Who are Rapport Therapeutics' major shareholders? Rapport Therapeutics' top institutional investors include T. Rowe Price Investment Management Inc. (4.25%), Goldman Sachs Group Inc. (3.41%), Siren L.L.C. (1.04%) and Siren L.L.C. (1.04%). View institutional ownership trends. How do I buy shares of Rapport Therapeutics? Shares of RAPP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rapport Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rapport Therapeutics investors own include Alpha Metallurgical Resources (AMR), Arch Biopartners (ARCH), Global X Copper Miners ETF (COPX), Hims & Hers Health (HIMS), Karuna Therapeutics (KRTX), Longboard Pharmaceuticals (LBPH) and Navios Maritime Partners (NMM). Company Calendar Last Earnings5/08/2025Today5/28/2025Next Earnings (Estimated)6/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RAPP Previous SymbolNASDAQ:RAPP CIK2012593 WebN/A Phone(857) 321-8020FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$32.67 High Stock Price Target$35.00 Low Stock Price Target$28.00 Potential Upside/Downside+232.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio45.91 Quick Ratio45.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares36,498,000Free FloatN/AMarket Cap$358.41 million OptionableN/A BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:RAPP) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe biggest threat isn’t ChinaWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe trade war twist nobody saw comingThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.